Business Context and Reporting Period
This Form 8-K Current Report was filed by Keros Therapeutics, Inc. on April 13, 2023. The filing reports a corporate governance event: the appointment of a new director to the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel and governance changes rather than financial performance.
Material Changes
The Board of Directors voted to increase its size to eight members and appointed Dr. Alpna Seth as a director, effective May 1, 2023. Dr. Seth was appointed as a Class II director with a term expiring at the 2025 annual meeting. She was also appointed to the Compensation Committee.
Compensation and Governance Details
- Stock Options: Dr. Seth received an initial grant to purchase 20,000 shares of common stock at the closing price on the grant date, vesting in equal quarterly installments over three years.
- Annual Grants: She is eligible for an annual option grant to purchase 10,000 shares in connection with future annual meetings.
- Cash Retainers: Dr. Seth will receive a $40,000 annual retainer for Board service and an additional $6,000 annual retainer for her role on the Compensation Committee.
- Indemnification: The Company entered into a standard indemnification agreement covering expenses, damages, and legal fees incurred in her capacity as a director.
Investor Verification Checklist
- Verify the effective date of Dr. Seth's appointment (May 1, 2023) and her term expiration (2025 annual meeting).
- Confirm the total number of shares subject to the initial option grant (20,000) and the vesting schedule (quarterly over three years).
- Review the updated composition of the Audit, Compensation, and Nominating and Corporate Governance Committees.
- Check the attached press release (Exhibit 99.1) for additional context on Dr. Seth's background and qualifications.